Negotiating complex contracts: research and development (R&D) funding and advance vaccine purchases for COVID-19 between 2020 and 2021
This article examines research and development (R&D) funding, the advance purchase of COVID-19 vaccines and the complex contracts that states signed with pharmaceutical companies. Drawing on information from the Centre for Global Health and the European Court of Auditors, the findings sugges...
Збережено в:
| Автор: | |
|---|---|
| Інші автори: | |
| Формат: | article |
| Мова: | spa |
| Опубліковано: |
2025
|
| Предмети: | |
| Онлайн доступ: | https://revistas.iaen.edu.ec/index.php/estado_comunes/article/view/395 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
Додати тег | _version_ | 1858495683950018560 |
|---|---|
| author | King Mantilla, Katiuska |
| author2 | Carranza-Barona, César |
| author2_role | author |
| author_facet | King Mantilla, Katiuska Carranza-Barona, César |
| author_role | author |
| collection | Revista de políticas y problemas públicos |
| dc.coverage.none.fl_str_mv | European Union, Latin America Unión Europea, América Latina |
| dc.creator.none.fl_str_mv | King Mantilla, Katiuska Carranza-Barona, César |
| dc.date.none.fl_str_mv | 2025-01-15 |
| dc.format.none.fl_str_mv | application/pdf text/html application/epub+zip text/xml |
| dc.identifier.none.fl_str_mv | https://revistas.iaen.edu.ec/index.php/estado_comunes/article/view/395 10.37228/estado_comunes.v1.n20.2025.395 |
| dc.language.none.fl_str_mv | spa |
| dc.publisher.none.fl_str_mv | Instituto de Altos Estudios Nacionales IAEN |
| dc.relation.none.fl_str_mv | https://revistas.iaen.edu.ec/index.php/estado_comunes/article/view/395/637 https://revistas.iaen.edu.ec/index.php/estado_comunes/article/view/395/638 https://revistas.iaen.edu.ec/index.php/estado_comunes/article/view/395/639 https://revistas.iaen.edu.ec/index.php/estado_comunes/article/view/395/698 |
| dc.rights.none.fl_str_mv | Derechos de autor 2025 Katiuska King Mantilla, César Carranza-Barona https://creativecommons.org/licenses/by-nc-sa/4.0 info:eu-repo/semantics/openAccess |
| dc.source.none.fl_str_mv | Estado & comunes; Vol. 1 No. 20 (2025): State contracts, strategic sectors and complex disputes; 37-58 Estado & comunes; Vol. 1 Núm. 20 (2025): Contratos del Estado, sectores estratégicos y disputas complejas; 37-58 2477-9245 1390-8081 10.37228/estado_comunes.v1.n20.2025 reponame:Revista de políticas y problemas públicos instname:Instituto de Altos Estudios Nacionales instacron:IAEN |
| dc.subject.none.fl_str_mv | Centro de Salud Global covid-19 economía política internacional Fosun Pharma multinacionales farmacéuticas Pfizer-BioNTech relaciones de poder sistema sanitario vacunas compras anticipadas hegemonía empresas farmacéuticas financiamiento Center for Global Health COVID-19 international political economy Fosun Pharma multinational pharmaceutical companies Pfizer-BioNTech power relations healthcare system vaccines advance purchases hegemony pharmaceutical companies financing |
| dc.title.none.fl_str_mv | Negotiating complex contracts: research and development (R&D) funding and advance vaccine purchases for COVID-19 between 2020 and 2021 Negociación de contratos complejos: financiamiento para investigación y desarrollo (I+D) y compras anticipadas de vacunas para la covid-19 entre 2020-2021 |
| dc.type.none.fl_str_mv | info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Text Artículos evaluados por doble pares ciegos Texto |
| description | This article examines research and development (R&D) funding, the advance purchase of COVID-19 vaccines and the complex contracts that states signed with pharmaceutical companies. Drawing on information from the Centre for Global Health and the European Court of Auditors, the findings suggest that pharmaceutical companies obtained public funds for vaccine development and took advantage of their privileged position to impose contractual clauses on countries, including production/distribution conditions and compensation for vaccine side effects. The findings suggest that the big winners during the pandemic were the pharmaceutical companies, that states did not benefit from the investment made in R&D, and that some Latin American countries accepted contractual impositions, including maintaining the confidentiality and non-disclosure of contracts. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | REVESTADOC_6f82eb15a077bccce8d50595d0756169 |
| identifier_str_mv | 10.37228/estado_comunes.v1.n20.2025.395 |
| instacron_str | IAEN |
| institution | IAEN |
| instname_str | Instituto de Altos Estudios Nacionales |
| language | spa |
| network_acronym_str | REVESTADOC |
| network_name_str | Revista de políticas y problemas públicos |
| oai_identifier_str | oai:revistas.iaen.edu.ec:article/395 |
| publishDate | 2025 |
| publisher.none.fl_str_mv | Instituto de Altos Estudios Nacionales IAEN |
| reponame_str | Revista de políticas y problemas públicos |
| repository.mail.fl_str_mv | . |
| repository.name.fl_str_mv | Revista de políticas y problemas públicos - Instituto de Altos Estudios Nacionales |
| repository_id_str | |
| rights_invalid_str_mv | Derechos de autor 2025 Katiuska King Mantilla, César Carranza-Barona https://creativecommons.org/licenses/by-nc-sa/4.0 |
| spelling | Negotiating complex contracts: research and development (R&D) funding and advance vaccine purchases for COVID-19 between 2020 and 2021Negociación de contratos complejos: financiamiento para investigación y desarrollo (I+D) y compras anticipadas de vacunas para la covid-19 entre 2020-2021 King Mantilla, KatiuskaCarranza-Barona, CésarCentro de Salud Globalcovid-19economía política internacionalFosun Pharmamultinacionales farmacéuticasPfizer-BioNTechrelaciones de podersistema sanitariovacunascompras anticipadashegemoníaempresas farmacéuticasfinanciamientoCenter for Global HealthCOVID-19international political economyFosun Pharmamultinational pharmaceutical companiesPfizer-BioNTechpower relationshealthcare systemvaccinesadvance purchaseshegemonypharmaceutical companiesfinancingThis article examines research and development (R&D) funding, the advance purchase of COVID-19 vaccines and the complex contracts that states signed with pharmaceutical companies. Drawing on information from the Centre for Global Health and the European Court of Auditors, the findings suggest that pharmaceutical companies obtained public funds for vaccine development and took advantage of their privileged position to impose contractual clauses on countries, including production/distribution conditions and compensation for vaccine side effects. The findings suggest that the big winners during the pandemic were the pharmaceutical companies, that states did not benefit from the investment made in R&D, and that some Latin American countries accepted contractual impositions, including maintaining the confidentiality and non-disclosure of contracts.Este artículo examina el financiamiento para la investigación y el desarrollo (I+D), la compra anticipada de vacunas contra la covid-19 y los contratos complejos que los Estados firmaron con las empresas farmacéuticas. A partir de información del Centro de Salud Global y el Tribunal de Cuentas Europeo, los hallazgos apuntan a que las farmacéuticas obtuvieron fondos públicos para el desarrollo de vacunas y aprovecharon su posición privilegiada para imponer cláusulas contractuales a los países. Las condiciones de la producción/distribución y las indemnizaciones por efectos secundarios de la vacuna son algunas de las cláusulas. Las conclusiones sugieren que los grandes ganadores durante la pandemia fueron las farmacéuticas, que los Estados no obtuvieron beneficios por la inversión realizada en la I+D y que algunos países de América Latina aceptaron imposiciones contractuales, entre ellas, mantener la confidencialidad y reserva de los contratos.Instituto de Altos Estudios Nacionales IAEN2025-01-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionTextArtículos evaluados por doble pares ciegosTextoapplication/pdftext/htmlapplication/epub+ziptext/xmlhttps://revistas.iaen.edu.ec/index.php/estado_comunes/article/view/39510.37228/estado_comunes.v1.n20.2025.395Estado & comunes; Vol. 1 No. 20 (2025): State contracts, strategic sectors and complex disputes; 37-58Estado & comunes; Vol. 1 Núm. 20 (2025): Contratos del Estado, sectores estratégicos y disputas complejas; 37-582477-92451390-808110.37228/estado_comunes.v1.n20.2025reponame:Revista de políticas y problemas públicosinstname:Instituto de Altos Estudios Nacionalesinstacron:IAENspahttps://revistas.iaen.edu.ec/index.php/estado_comunes/article/view/395/637https://revistas.iaen.edu.ec/index.php/estado_comunes/article/view/395/638https://revistas.iaen.edu.ec/index.php/estado_comunes/article/view/395/639https://revistas.iaen.edu.ec/index.php/estado_comunes/article/view/395/698European Union, Latin AmericaUnión Europea, América LatinaDerechos de autor 2025 Katiuska King Mantilla, César Carranza-Baronahttps://creativecommons.org/licenses/by-nc-sa/4.0info:eu-repo/semantics/openAccess2025-12-17T21:36:51Zoai:revistas.iaen.edu.ec:article/395Portal de revistashttps://revistas.iaen.edu.ec/index.php/estado_comunesUniversidad públicahttps://www.iaen.edu.ec/https://revistas.iaen.edu.ec/index.php/estado_comunes/oaiEcuadoropendoar:2025-12-17T21:36:51falsePortal de revistashttps://revistas.iaen.edu.ec/index.php/estado_comunesUniversidad públicahttps://www.iaen.edu.ec/https://revistas.iaen.edu.ec/index.php/estado_comunes/oai.Ecuadoropendoar:2025-12-17T21:36:51Revista de políticas y problemas públicos - Instituto de Altos Estudios Nacionalesfalse |
| spellingShingle | Negotiating complex contracts: research and development (R&D) funding and advance vaccine purchases for COVID-19 between 2020 and 2021 King Mantilla, Katiuska Centro de Salud Global covid-19 economía política internacional Fosun Pharma multinacionales farmacéuticas Pfizer-BioNTech relaciones de poder sistema sanitario vacunas compras anticipadas hegemonía empresas farmacéuticas financiamiento Center for Global Health COVID-19 international political economy Fosun Pharma multinational pharmaceutical companies Pfizer-BioNTech power relations healthcare system vaccines advance purchases hegemony pharmaceutical companies financing |
| status_str | publishedVersion |
| title | Negotiating complex contracts: research and development (R&D) funding and advance vaccine purchases for COVID-19 between 2020 and 2021 |
| title_full | Negotiating complex contracts: research and development (R&D) funding and advance vaccine purchases for COVID-19 between 2020 and 2021 |
| title_fullStr | Negotiating complex contracts: research and development (R&D) funding and advance vaccine purchases for COVID-19 between 2020 and 2021 |
| title_full_unstemmed | Negotiating complex contracts: research and development (R&D) funding and advance vaccine purchases for COVID-19 between 2020 and 2021 |
| title_short | Negotiating complex contracts: research and development (R&D) funding and advance vaccine purchases for COVID-19 between 2020 and 2021 |
| title_sort | Negotiating complex contracts: research and development (R&D) funding and advance vaccine purchases for COVID-19 between 2020 and 2021 |
| topic | Centro de Salud Global covid-19 economía política internacional Fosun Pharma multinacionales farmacéuticas Pfizer-BioNTech relaciones de poder sistema sanitario vacunas compras anticipadas hegemonía empresas farmacéuticas financiamiento Center for Global Health COVID-19 international political economy Fosun Pharma multinational pharmaceutical companies Pfizer-BioNTech power relations healthcare system vaccines advance purchases hegemony pharmaceutical companies financing |
| url | https://revistas.iaen.edu.ec/index.php/estado_comunes/article/view/395 |